| Literature DB >> 32971239 |
Jurandy Júnior Ferraz de Magalhães1, Renata Pessoa Germano Mendes2, Caroline Targino Alves da Silva2, Severino Jefferson Ribeiro da Silva2, Klarissa Miranda Guarines2, Lindomar Pena3.
Abstract
BACKGROUND: South America is the current epicenter of COVID-19 pandemic. Yet, the epidemiological and clinical features of the disease have not been described in Brazil, the third most affected country in the world.Entities:
Keywords: Clinical characteristics; Clinics; Coronavirus disease 2019; Demographics; Epidemiology; SARS-CoV-2
Year: 2020 PMID: 32971239 PMCID: PMC7522369 DOI: 10.1016/j.tmaid.2020.101884
Source DB: PubMed Journal: Travel Med Infect Dis ISSN: 1477-8939 Impact factor: 6.211
Fig. 1Spatial analysis of COVID-19 cases in Pernambuco state, Brazil. Fig. 1A shows the spatial distribution of COVID-19 cases in Recife, Pernambuco capital as heat map. The Kernel Density Estimate was used to show the areas with the highest concentration of cases associated with the incidence of the disease in some neighborhoods. Fig. 1B shows a graduated map with information on the average nominal monthly household income converted into the amount of minimum wages. Fig. 1C shows the cities with COVID-19 positive cases in the State of Pernambuco.
Fig. 2Epidemiological features of COVID-19 patients (n = 557) in Pernambuco, Brazil. A) Cumulative number of COVID-19 infected and deceased patients recorded weekly since the first diagnostic. B) Age distribution in COVID-19 lethal and non-lethal cases.
Fig. 3Clinical features of COVID-19 patients (n = 557) in Pernambuco, Brazil. A) Main symptoms presented at the time of patient notification. B) Symptoms distribution according to the age group.
Fig. 4Virus shedding patterns at the time of diagnosis.
A) Viral load in nasopharyngeal swabs according to the date of symptoms onset. B) Viral load in severe and mild patients according to the date of symptoms onset. *p <
0.05.
Epidemiological features of COVID-19 patients (n = 557) in Pernambuco, Brazil.
| Age | <1 year | 1–10 | 11–20 | 21–30 | 31–40 | 41–50 | 51–60 | 61–70 | 71–80 | 81–90 | 91–100 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 304 (54.58) | 1 (20.00) | 3 (50.00) | 2 (66.66) | 35 (59.32) | 77 (60.15) | 60 (49.59) | 53 (52.48) | 34 (51.52) | 18 (56.25) | 18 (58.06) | 3 (60.00) |
| Male | 253 (45.42) | 4 (80.00) | 3 (50.00) | 1 (33.34) | 24 (40.68) | 51 (39.85) | 61 (50.41) | 48 (47.52) | 32 (48.48) | 14 (43.75) | 13 (41.94) | 2 (40.00) |
| Self-isolation | 282 (50.63) | 3 (60.00) | 2 (33.33) | 1 (33.33) | 48 (81.35) | 88 (68.75) | 70 (57.85) | 50 (49.50) | 10 (15.15) | 5 (15.62) | 4 (12.90) | 1 (20.00) |
| Hospital wards | 150 (26.93) | 2 (40.00) | 4 (66.66) | – | 6 (10.17) | 24 (18.75) | 39 (32.23) | 24 (23.76) | 27 (40.91) | 14 (43.75) | 10 (32.26) | – |
| ICU | 30 (5.38) | – | – | – | 2 (3.38) | 1 (0.78) | 3 (2.48) | 8 (7.92) | 6 (9.09) | 4 (12.50) | 5 (16.13) | 1 (20.00) |
| Death | 59 (10.59) | – | – | 1 (33.33) | – | 3 (2.34) | 4 (3.31) | 11 (10.89) | 18 (27.27) | 8 (25.00) | 12 (38.71) | 2 (40.00) |
| Recovered | 36 (6.46) | – | – | 1 (33.33) | 3 (5.08) | 12 (9.36) | 5 (4.13) | 8 (7.92) | 5 (7.58) | 1 (3.13) | – | 1 (40.00) |
Numbers between parentheses indicate percentage of patients in each age group.
Fig. 5Clinical comorbidities in COVID-19 positive patients.